

10 January 2025



ASX Limited
20 Bridge St
Sydney NSW 2000
Australia

NZ RegCo
11 Cable St
Wellington
New Zealand

Request for trading halt: PACIFIC EDGE LIMITED (ASX Code: PEB, NZX Code: PEB)

We request a trading halt to be applied to our securities: (ISIN: NZPEBE0002S1) under ASX Listing Rule 17.1 and NZX Listing Rule 9.9.1(a) and set out below details of the request as per the rules of each of ASX and NZX.

We would like the trading halt to commence from: the commencement of trading on the ASX and NZX today (10 January 2025) ahead of the market open.

Reasons for trading halt: The company is aware Novitas, the Medicare Administrative Contractor with jurisdiction for the company's US laboratory, has finalized the draft Local Coverage Determination (LCD) 'Genetic Testing for Oncology' (DL 39365) under a new title 'Genetic Testing in Oncology: Specific Tests' (L 39365) covering the reimbursement of Cxbladder tests by Medicare.

Pacific Edge is currently reviewing the LCD and the associated documentation and needs time to assess the implications of the announcement, consult with US legal advisers and industry partners, and prepare an announcement that provides context to investors.

It expects to provide an update to the market ahead of the opening of trading on Monday 13 January 2025.

How long we want the trading halt to last: until the opening of trading on the NZX and ASX on Monday 13 January 2025.

The event we expect to happen that will end the trading halt: The release of a statement to the market before the market open.

Other information necessary to inform the market about the trading halt or that ASX or NZ RegCo have requested: see the statement below on the information in the market memorandum to be released in relation to the trading halt.

Information to include in any market memorandum relating to the halt:

Pacific Edge is aware Novitas, the Medicare Administrative Contractor with jurisdiction for the company's US laboratory, has finalized the draft Local Coverage Determination (LCD) 'Genetic Testing

for Oncology' (DL 39365) under a new title 'Genetic Testing in Oncology: Specific Tests' (L39365) covering the reimbursement of its Cxbladder tests by Medicare.

Pacific Edge has requested a trading halt of the company's shares on both the NZX and ASX while it reviews the LCD and the associated documentation.

The determination covers significant new information and Pacific Edge needs time to assess the implications of the announcement, consult with US legal advisers and industry partners, and prepare an announcement that provides context to investors.

Pacific Edge is currently reviewing the information and expects to provide an update to the market ahead of the opening of trading on Monday 13 January 2025 and expects the trading halt to be lifted at that time.

In the meantime, the company is not in a position to make any further comment.

We confirm that we are not aware of any reason why the trading halt should not be granted.

Yours sincerely

DocuSigned by:

38FA000A715B41F...
Grant Gibson

Chief Financial Officer
Pacific Edge Limited

Trading halt requests should be emailed to NZ RegCo at: issuer@nzregco.com, and to the entity's designated Listings Compliance Adviser and the relevant general trading halt email address at ASX: tradinghaltssydney@asx.com.au, tradinghaltsmelbourne@asx.com.au or tradinghaltspertth@asx.com.au